This indicates another successful year and a probable hike in dividend. Management expects fiscal 2021's adjusted operational sales to grow year over year by 12.5% to 13.5%, and adjusted diluted earnings per share to jump 18.4% to 19.6% from the year-ago period to $9.50 to $9.60. market contributed to 50% of total sales during the quarter. The segment revived with a market recovery for medical devices and elective procedures that were otherwise deferred during the pandemic. The company had another stellar second quarter wherein it saw double-digit growth in all three of its segments, with a tremendous year-over-year increase of 63% in the medical device segment. Johnson & Johnson's strength lies in its diversified business, comprised of three segments: consumer health, pharmaceuticals, and medical devices. (Payout ratio helps determine if a company's dividend payments are sustainable the lower, the better.) Its dividend payout ratio (based on cash flow) of 38.9% reveals the company is stable enough to continue paying dividends to its shareholders. It recently increased its quarterly dividend again by 5% to $1.06 per share. The company continues to grow, so investors can be assured dividend payments won't be stopping anytime soon. Its strong financials have helped the company pay dividends consistently for 59 years.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |